Zhang Yong-Jie, Min Qi, Huang Ying, Liu Huai-Dong, Zhu Zi-Yuan, Jiang Fu-Jin, Hua Hai-Qing
Huai'an Hospital Affiliated to Xuzhou Medical University, Huai'an 223002, Jiangsu, China.
General Hospital of Eastern Theater Command Affiliated to Nanjing University of Chinese Medicine, Nanjing 210002, Jiangsu, China.
Evid Based Complement Alternat Med. 2020 Jun 29;2020:8274021. doi: 10.1155/2020/8274021. eCollection 2020.
To explore whether acupuncture and moxibustion can prevent disease progression of advanced gastric cancer patients completing second-line chemotherapy and, if so, the related mechanism.
Progression-free survival (PFS) and overall survival (OS) were main outcome measures. The real-time quantitative PCR was used to detect the expression of genes including T-bet, IFN-, GATA3, and IL-4 in peripheral blood mononuclear cells (PBMCs). IL-4, IL-6, Ca199, CRP, and IFN- in plasma levels were checked.
170 patients were randomly assigned in a 3 : 2 ratio to receive either acupuncture and moxibustion or sham acupuncture until progression. 135 patients were included in the primary analysis. Both PFS and OS in treatment group were proven to be better than control group. Acupuncture and moxibustion promoted typical Th1 cells drifting, as confirmed by increased T-bet/IFN- and decreased GATA3/IL-4 in mRNA levels from PBMCs, as well as upregulating IFN- and downregulating IL-4 in plasma levels. IL-6, Ca199, and CRP in plasma levels were also reduced by acupuncture and moxibustion.
Acupuncture and moxibustion can prolong PFS and OS of advanced gastric cancer patients completing second-line chemotherapy by reversing Th1/Th2 shift and attenuating inflammatory responses.
探讨针灸能否预防晚期胃癌患者完成二线化疗后的疾病进展,若能,则探讨其相关机制。
主要观察指标为无进展生存期(PFS)和总生存期(OS)。采用实时定量PCR检测外周血单个核细胞(PBMCs)中T-bet、IFN-、GATA3和IL-4等基因的表达。检测血浆中IL-4、IL-6、Ca199、CRP和IFN-水平。
170例患者按3∶2随机分组,分别接受针灸或假针灸治疗,直至病情进展。135例患者纳入初步分析。结果显示,治疗组的PFS和OS均优于对照组。针灸促进典型的Th1细胞漂移,PBMCs中mRNA水平的T-bet/IFN-升高、GATA3/IL-4降低,以及血浆中IFN-上调、IL-4下调均证实了这一点。针灸还降低了血浆中IL-6、Ca199和CRP水平。
针灸可通过逆转Th1/Th2偏移和减轻炎症反应,延长晚期胃癌患者完成二线化疗后的PFS和OS。